Venture capitalist Bryan Johnson stopped taking the drug rapamycin in September 2024 following side effects such as skin infections and abnormal blood lipids, according to Scientific American. This reversal underscores a growing divide between Silicon Valley’s rapid self-experimentation and the slower, more rigorous process of clinical longevity research.
Why are tech influencers testing unproven longevity drugs?
Wealthy entrepreneurs and venture capitalists are increasingly using their own bodies as testing grounds for anti-aging interventions. This practice often occurs before clinical evidence establishes widespread safety or efficacy for the general public.
Bryan Johnson, the 48-year-old, added rapamycin to his regimen in 2019. He used various doses and schedules to attempt to extend his lifespan, according to Scientific American. However, he discontinued the drug after identifying several physiological changes.
Rapamycin was originally developed as an immunosuppressant to prevent organ rejection in transplant patients, not as an anti-aging supplement.
What are the health risks of self-administered longevity treatments?
The primary risk of the longevity craze is the lack of controlled clinical oversight. When influencers share biomarker charts and “biological age” claims, they may inadvertently make unproven treatments appear safer than they are.
Johnson reported several specific complications following his rapamycin use. In a post on X, he stated that after dosage adjustments failed to resolve the issues, he suspected the drug caused recurring skin infections, elevated glucose levels, abnormal blood lipids, and a faster resting heart rate.
Other high-profile figures have also issued warnings regarding supplement safety:
- Tim Ferriss and Kevin Rose: In March, the entrepreneur and venture capitalist used a podcast to caution listeners about supplements containing 1,3-butanediol, comparing the risk to drinking unregulated moonshine.
- FDA Warnings: The Food and Drug Administration has issued warnings against “young plasma” infusions, a treatment frequently discussed in elite wellness circles.
The conflict of interest in longevity marketing
The line between personal experimentation and commercial marketing is often blurred. Some longevity influencers who promote specific protocols also sell their own branded supplements, creating a financial incentive to validate unproven claims.
How will longevity science evolve in the future?
The future of aging research likely depends on a transition from anecdotal social media reports to formal, controlled human trials. While the goal remains improving “healthspan”—the years lived without chronic disease—scientists argue that safety must come first.
Current scientific efforts focus on legitimate studies designed to answer whether existing drugs can safely delay age-related diseases. Unlike the “shadow experiments” seen in Silicon Valley, these trials require strict regulatory adherence and peer-reviewed verification.
| Feature | Influencer Experimentation | Clinical Research |
|---|---|---|
| Primary Goal | Personal optimization | Public health safety/efficacy |
| Methodology | Self-testing/Anecdotal reports | Controlled human trials |
| Oversight | Minimal/Social Media | FDA and Institutional Review Boards |
Frequently Asked Questions
What is rapamycin used for?
Rapamycin is an immunosuppressant drug used to prevent organ rejection in transplant patients. Some researchers are investigating its potential to affect aging, but this is not yet clinically proven for that purpose.
What is “biological age”?
Biological age is a metric used by some wellness practitioners to estimate how much a person’s cells have aged compared to their chronological age. It is often based on biomarkers like DNA methylation or blood chemistry.
Is the FDA approving anti-aging drugs?
The FDA does not currently approve drugs specifically for “anti-aging.” They approve medications for specific diseases and have issued warnings against unproven treatments like young plasma infusions.
Want to stay updated on the latest in health science and biotech? Subscribe to our newsletter for deep dives into emerging medical trends.
